<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>How Is ResMed's Stock Performance Compared to Other Healthcare Stocks?</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>How Is ResMed's Stock Performance Compared to Other Healthcare Stocks?</h1>
  <ul>
<li>Further, its non-GAAP EPS soared 22.6% year-over-year to $2.55, exceeding the consensus estimates by 3.7%.</li>
<li>RMD’s mean price target of $289.25 suggests a 7.1% upside potential from current price levels.</li>
<li>ResMed’s overall net revenues for the quarter grew 10.2% year-over-year to $1.35 billion, surpassing the Street expectations by 1.9%.</li>
<li>22 and is currently trading 8.1% below that peak.</li>
<li>ResMed’s stock prices gained 2.7% in the trading session following the release of its impressive Q4 results on Jul.</li>
<li>Moreover, ResMed has also significantly outperformed its peer, Becton, Dickinson and Company’s (BDX) 17.6% decline in 2025 and 20.7% plunge over the past 52 weeks.</li>
<li>RMD stock prices have surged 18.1% in 2025 and 7.8% over the past 52 weeks, outpacing XLV’s marginal 39 bps uptick on a YTD basis and 11.4% decline over the past year.</li>
</ul>
<p><a href="https://finance.yahoo.com/m/18e5adce-bfb3-30fe-a075-7f55ac01f1bc/how-is-resmed%27s-stock.html">Source</a> · 2025-09-15T06:07:58+00:00</p>
</body>
</html>